RMD

Rating buyAI Memo

ResMed

As of 2026-01-31/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-01-31 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

medium

Horizon

—

Key catalyst

FY26 Q2 / near-term quarterly results (assumed window) • 2026-04-30

Expected move: +43%

Biggest risk

Bear case assumes weaker reimbursement, inventory destocking by large purchasers, or adverse regulatory actions that compress revenue and margins and push valuation toward the analyst low.

Invalidation

Break below $225 or thesis failure.

What would change my mind?

Bull case assumes continued subscription/ARR cadence acceleration, sustained device sales growth, margin expansion from software mix, and successful market share gains versus incumbents—driving the stock toward analyst highs.

Research note

Recommendation

buy

Confidence

medium

As of

2026-01-31

Base target

$296

p=60%

Bull target

$352

p=25%

Bear target

$225

p=15%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

FY26 Q2 / near-term quarterly results (assumed window)
Regulatory / reimbursement risk in Europe and North America
Adoption of cloud/AI care-management services and device refresh cycles

BearKey bullets

Device recall or manufacturing disruption
Reimbursement or regulatory changes in major markets
Slower-than-expected uptake of subscription services

WatchKey bullets

ANCHOR: {"price": 258.31, "timestamp_utc": "2026-01-31T07:14:32+00:00", "source": "broker_last"} ANALYST_TARGETS_REVIEWED: true Targets are set relative to the authoritative anchor above: base_target (295.75) aligns with the analyst median and sits inside the consensus low/high (225.0/351.75), bull_target equals the analyst high (351.75) and bear_target equals the analyst low (225.0); method: scenario targets use the injected anchor and the analyst low/median/high as sanity checks (see consensus snippets) [#SERP-5].

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $296 (p=60%)

Bull/Bear spread: +71% / +9%

Vs latest close: Bull +71% · Base +43% · Bear +9%

Scenario probabilities

Bull Target: $352 (p=25%)Base Target: $296 (p=60%)Bear Target: $225 (p=15%)

Commentary

Market commentary is mixed-to-positive: consensus median target sits above the current anchor, reflecting analyst optimism around subscription growth and device cycles [#SERP-5]. Some outlets still cite a wide range of outcomes (low-to-high dispersion), indicating uncertainty and sensitivity to guidance and reimbursement trends [#SERP-2].

As of 2026-01-31 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Bear case assumes weaker reimbursement, inventory destocking by large purchasers, or adverse regulatory actions that compress revenue and margins and push valuation toward the analyst low.

Drivers

Scannable catalysts and supporting factors

FY26 Q2 / near-term quarterly results (assumed window)
Regulatory / reimbursement risk in Europe and North America
Adoption of cloud/AI care-management services and device refresh cycles

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-01-31Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$295.75

Range (USD)

$225.00 - $351.75

Count

Query: ResMed Inc Common (RMD) analyst consensus price target high low average

ResMed Inc. (RMD) Stock Price, News, Quote & History
Search result #1
Q2. FY26. 0. 500M. 1B. View More. Analyst Insights: RMD. View More. Analyst Price Targets. 225.00 Low. 296.40 Average. 258.31 Current. 345.00 High. Analyst ...
Open source
ResMed (RMD) Stock Forecast & Price Target - Investing.com
Search result #2
According to projections from 15 analysts, the average 12-month price target for ResMed is 292.67, with a high estimate of 345 and a low estimate of 225.
Open source
ResMed (RMD) Stock Forecast and Price Target 2026 - MarketBeat
Search result #3
The highest price target for RMD is $345.00, while the lowest price target for RMD is $265.00. The average price target represents a forecasted upside of 15.58% ...
Extracted: $345.00, $265.00Open source
Resmed (RMD) Stock Forecast, Price Targets and Analysts Predictions
Search result #4
The average price target is $295.75 with a high forecast of $345.00 and a low forecast of $260.00. The average price target represents a 15.77% change from the ...
Extracted: $295.75, $345.00, $260.00Open source
RMD / ResMed Inc. (NYSE) - Forecast, Price Target, Estimates ...
Search result #5
The average one-year price target for ResMed Inc. is $300.11. The forecasts range from a low of $227.25 to a high of $351.75. To come up with their price ...
Extracted: $300.11, $227.25, $351.75Open source
ResMed Inc. Analyst Estimates - RMD - MarketWatch
Search result #6
Stock Price Targets. High, $345.00. Median, $310.25. Low, $225.00. Average, $303.05. Current Price, $257.72. Yearly Numbers. Estimates. RMD will report 2026 ...
Extracted: $345.00, $310.25, $225.00, $303.05, $257.72Open source

Scenarios

Bull Target (Scenario probability)

$352 / p=25% prob

Base Target (Scenario probability)

$296 / p=60% prob

Bear Target (Scenario probability)

$225 / p=15% prob

Price $206 as of 2026-05-27

Nearest Scenario: Bear (∆ 9%)

Targets vs latest close: Bull +71% · Base +43% · Bear +9%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Short-term Catalysts

Next few weeks

FY26 Q2 / near-term quarterly results (assumed window)
2026-04-30
Company quarterly results and guidance for FY26 Q2; timing not formally published in this brief so a conservative end-of-window date is used; results may move shares on revenue/gross-margin and subscription metrics [#SERP-6].
Prob 70% • Move 8% • Priced-in 40%
Regulatory / reimbursement risk in Europe and North America
2026-04-30
Changes to reimbursement policy, device recalls, or competitive pricing pressure (e.g., respirator supplier dynamics) could materially reduce near-term revenue; timing uncertain so short conservative window used [#SERP-2].
Prob 40% • Move -18% • Priced-in 35%

Long-term Catalysts

Months to a year

Adoption of cloud/AI care-management services and device refresh cycles
2027-01-31
Accelerating ARR from cloud-based sleep/respiratory management and device refreshes could drive outsized revenue and margin expansion over 12+ months; adoption and reimbursement trends will determine capture [#SERP-4].
Prob 55% • Move 25% • Priced-in 30%

Risks

Device recall or manufacturing disruption
Reimbursement or regulatory changes in major markets
Slower-than-expected uptake of subscription services

Peers

Symbol	Summary
PHG	Philips (respiratory/connected care) — large competitor in hospital and home respiratory segments; regulatory dynamics and service offerings provide a comparable strategic backdrop.
FPH	Fisher & Paykel Healthcare — focused on respiratory devices and growing connected-care offerings, useful comparator for product-cycle and geographic exposure.
INSP	Inspire Medical Systems — narrower therapeutic focus (implantable sleep therapy) but comparable end-market exposure and reimbursement sensitivity.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: ResMed Inc Common (RMD) analyst consensus price target high low average
Analysis date: 2026-01-31

AI Stock Memo: RMD - ResMed - RankAlpha